1. Home
  2. IMCR vs TYRA Comparison

IMCR vs TYRA Comparison

Compare IMCR & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

N/A

Current Price

$26.33

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

N/A

Current Price

$20.09

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IMCR
TYRA
Founded
2008
2018
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
IMCR
TYRA
Price
$26.33
$20.09
Analyst Decision
Buy
Strong Buy
Analyst Count
12
15
Target Price
★ $59.30
$47.45
AVG Volume (30 Days)
414.0K
★ 530.2K
Earning Date
11-06-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 30.39
N/A
EPS
★ N/A
N/A
Revenue
★ $249,428,000.00
N/A
Revenue This Year
$9.28
N/A
Revenue Next Year
$9.91
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 43.05
N/A
52 Week Low
$26.53
$18.25
52 Week High
$40.71
$40.65

Technical Indicators

Market Signals
Indicator
IMCR
TYRA
Relative Strength Index (RSI) 32.57 43.93
Support Level N/A $18.46
Resistance Level $31.75 $22.69
Average True Range (ATR) 1.46 1.15
MACD -0.46 -0.08
Stochastic Oscillator 9.12 19.25

Price Performance

Historical Comparison
IMCR
TYRA

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: